RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Guardant Health Stock

Guardant Health Stocks 2024

Guardant Health Stocks

111.99 M

Ticker

GH

ISIN

US40131M1099

WKN

A2N5RY

In 2024, Guardant Health had 111.99 M outstanding stocks, a 0% change from the 111.99 M stocks in the previous year.

The Guardant Health Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e111.99
2028e111.99
2027e111.99
2026e111.99
2025e111.99
2024e111.99
2023111.99
2022102.2
2021101.3
202097.5
201990.6
201885.8
201783.6
201683.6

Guardant Health shares outstanding

The number of shares was Guardant Health in 2023 — This indicates how many shares 111.988 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Guardant Health earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Guardant Health's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Guardant Health’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Guardant Health's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Guardant Health Aktienanalyse

What does Guardant Health do?

Guardant Health Inc is an American company specializing in the development of non-invasive diagnostic tests for cancer. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The two founders had previously successfully founded a company specialized in the development of blood tests for pregnancies. Guardant Health's goal is to detect traces of cancer cells in the blood of patients to enable early cancer diagnosis. Based on the liquid biopsy tests offered by the company, doctors can identify tumor cells and genetic mutations without relying on invasive methods such as tissue sampling. This allows for faster diagnosis and quicker treatment decision-making. Guardant Health's business model is based on the commercialization of its liquid biopsy tests, which are based on specially developed DNA sequencing methods. The company offers both diagnostic tests that can aid in cancer identification, as well as tests that can help doctors monitor the success of cancer therapies. Guardant Health has directed its offerings towards multiple products and divisions, including Guardant360, GuardantOmni, and GuardantReveal. Each of these products aims to solve specific challenges related to cancer diagnosis and treatment. Guardant360 is a diagnostic test specifically developed to help doctors sequence the DNA of cancer cells in the blood of patients and identify the genetic changes contributing to tumor growth. On the other hand, GuardantOmni is a liquid biopsy test that targets a broader range of cancer types. It enables a comprehensive genetic scan of cancer cells in the blood to identify specific mutations that can aid in tracking disease progression and selecting appropriate therapies. GuardantReveal is a test aimed at monitoring patients at higher risk of cancer. The test can be used to detect early signs of tumors in patients who are at higher risk due to their family history, age, or other factors. Guardant Health has achieved considerable success in the field of liquid biopsy detection in recent years. Currently, more than 100,000 patients worldwide have access to Guardant Health's liquid biopsy-based tests. The company is based in Redwood City, California, and employs over 1,000 employees. It has a broad investor base, including The SoftBank Vision Fund, Sequoia Capital, Lightspeed Venture Partners, and Khosla Ventures. Overall, the company has raised over $550 million in funding. Guardant Health aims to revolutionize the world of cancer diagnostics and treatment. By radically changing the process of diagnosing and monitoring cancer patients, the company aims to improve the survival rate of cancer patients and make cancer treatment more effective overall. Guardant Health ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Guardant Health's Shares Outstanding

Guardant Health's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Guardant Health’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Guardant Health’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Guardant Health’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Guardant Health stock

How many stocks are there of Guardant Health?

The current number of stocks of Guardant Health is 111.99 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Guardant Health are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Guardant Health evolved in recent years?

The number of shares of Guardant Health has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Guardant Health as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Guardant Health?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Guardant Health pay?

Over the past 12 months, Guardant Health paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Guardant Health is expected to pay a dividend of 0 USD.

What is the dividend yield of Guardant Health?

The current dividend yield of Guardant Health is .

When does Guardant Health pay dividends?

Guardant Health pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Guardant Health?

Guardant Health paid dividends every year for the past 0 years.

What is the dividend of Guardant Health?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Guardant Health located?

Guardant Health is assigned to the 'Health' sector.

Wann musste ich die Aktien von Guardant Health kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Guardant Health from 9/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Guardant Health pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Guardant Health in the year 2023?

In the year 2023, Guardant Health distributed 0 USD as dividends.

In which currency does Guardant Health pay out the dividend?

The dividends of Guardant Health are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Guardant Health

Our stock analysis for Guardant Health Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Guardant Health Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.